Nuo Therapeutics, Inc. (AURX) intrinsic value & 10-year financials
Nuo Therapeutics, Inc. (AURX) has a Graham intrinsic value of $8.97 per share. At $1.30 on Oct 17, 2026, the stock trades 86% below that value. Over the last 10 fiscal years revenue grew 21.0% a year to $3.3M, with an average return on invested capital of 91.2%.
- Graham intrinsic value
- $8.97
- Share price (Oct 17, 2026)
- $1.30
- Price vs Graham value
- 86% below
- Market cap
- $39.4M
- Revenue (FY2025)
- $3.3M
- Revenue growth (10-yr CAGR)
- 21.0%
- ROIC (10-yr avg)
- 91.2%
- Free cash flow (FY2025)
- -$1.1M
AURX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.3M | -$2.5M | — | -$1.1M | -76.0% | 434.9% |
| FY2024 | $1.4M | -$2.3M | — | -$2.4M | -180.0% | -816.5% |
| FY2023 | $608.5K | -$3.2M | — | -$3.2M | -520.6% | -945.2% |
| FY2022 | $112.2K | -$3.2M | — | -$3.8M | -2958.2% | 2938.5% |
| FY2021 | $0 | -$90.7K | -$0.03 | -$120.0K | — | 14.6% |
| FY2020 | $0 | -$90.9K | $0.27 | -$53.8K | — | 44.1% |
| FY2019 | $146.2K | -$1.2M | -$0.05 | -$921.7K | -663.0% | 150.1% |
| FY2018 | $1.4M | -$1.5M | -$0.07 | — | -109.8% | -769.2% |
| FY2017 | $721.0K | -$15.0M | -$1.02 | — | -2154.4% | -231.0% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Nuo Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Nuo Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just 7.4% ROIC.
Nuo Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Nuo Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $8.97 per share.